Frankfurt
15.05.25 | 09:15
0,809 Euro
+0,12 % +0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | DIAMYD MEDICAL AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated | 3 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 05.05. | DIAMYD MEDICAL AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million | 8 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million | 3 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million | 2 | Cision News | ||
| 29.04. | DIAMYD MEDICAL AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Last day of the subscription period in Diamyd Medicals rights issue | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 1 | Cision News | ||
| 25.04. | Diamyd Medical AB (publ): Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026 | 72 | GlobeNewswire (Europe) | The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy... ► Artikel lesen | |
| 22.04. | DIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue | 2 | Cision News | ||
| 21.04. | Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout | 266 | PR Newswire | STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's... ► Artikel lesen | |
| 17.04. | DIAMYD MEDICAL AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone | 1 | Cision News | ||
| 15.04. | Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 122 | GlobeNewswire (Europe) | The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent... ► Artikel lesen | |
| 14.04. | DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue | 1 | Cision News | ||
| 09.04. | Diamyd Medical AB (publ): Quarterly Report 2 24/25 | 102 | GlobeNewswire (Europe) | Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3... ► Artikel lesen | |
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 130 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 21.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 1 | Cision News | ||
| 17.03. | DIAMYD MEDICAL AB: Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025 | 1 | Cision News | ||
| 13.03. | Diamyd Medical AB (publ): Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project | 130 | GlobeNewswire (Europe) | Diamyd Medical, in collaboration with Mainly AI and ASSET partners, highlights meaningful progress in AI-driven screening and risk prediction for Type 1 Diabetes at the Advanced Technologies & Treatments... ► Artikel lesen | |
| 10.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 3 | Cision News | ||
| 28.02. | DIAMYD MEDICAL AB: The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million | 3 | Cision News |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 162,40 | -0,12 % | Aktien New York Ausblick: Zolleinigung bringt neuen Schwung - Pharma schwach | NEW YORK (dpa-AFX) - Eine Einigung im Zollstreit zwischen den USA und China beflügelt am Montag die New Yorker Börsen. Die beiden größten Volkswirtschaften der Welt kappen die gegenseitig verhängten... ► Artikel lesen | |
| INNOCAN PHARMA | 0,108 | +3,37 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| ABBOTT LABORATORIES | 118,92 | -0,29 % | Minimaler Kursabschlag bei der Abbott Laboratories-Aktie (115,0030 €) | Wenig Kursbewegung aktuell bei der Abbott Laboratories-Aktie . Das Wertpapier notiert gegenwärtig bei 128,54 US-Dollar. Ein geringes Minus von 0,40 Prozent zeigt die Kurstafel für der Anteilsschein... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,620 | +7,83 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen | |
| ZOETIS | 142,70 | -0,46 % | BTIG maintains Buy on Zoetis stock with $200 target | ||
| CRESCO LABS | 0,619 | -4,33 % | Cresco Labs slips after delaying Q1 earnings call | ||
| CSPC PHARMA | 0,639 | -3,50 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION | ||
| TONIX PHARMACEUTICALS | 20,200 | -1,94 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced... ► Artikel lesen | |
| AMARIN | 8,850 | -5,85 % | AMARIN CORP PLC - 8-K, Current Report | ||
| NEKTAR THERAPEUTICS | 0,592 | -2,63 % | H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target | ||
| AXSOME THERAPEUTICS | 92,84 | -3,21 % | Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone | WASHINGTON (dpa-AFX) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced that it has entered into a $570 million term loan and revolving credit facility with funds managed... ► Artikel lesen | |
| WUXI BIOLOGICS | 2,770 | +1,26 % | WuXi Biologics Ireland: Delivering Measurable Sustainability Progress Through Purposeful Innovation | From renewable energy and workforce diversity to local partnerships and sustainable technology, WuXi Biologics' Dundalk site is redefining responsible growth in biomanufacturing.
DUNDALK... ► Artikel lesen | |
| JAGUAR HEALTH | 5,460 | -11,51 % | Jaguar Health, Inc.: Jaguar Health Reports First Quarter 2025 Financials | The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 15,555 | -1,18 % | Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders | ||
| DAIICHI SANKYO | 20,680 | +0,19 % | AstraZeneca, Daiichi Sankyo Report Positive Results From DESTINY-Breast11 Phase III Study Of Enhertu | LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) and Daiichi Sankyo Company Limited (DSKYF.PK) Wednesday reported positive results from the DESTINY-Breast11 Phase III study of Enhertu. The study met... ► Artikel lesen |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+0,12 %) liegt der Kurs bei 0,809 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.